CA2258898C - Microchip drug delivery devices - Google Patents

Microchip drug delivery devices Download PDF

Info

Publication number
CA2258898C
CA2258898C CA002258898A CA2258898A CA2258898C CA 2258898 C CA2258898 C CA 2258898C CA 002258898 A CA002258898 A CA 002258898A CA 2258898 A CA2258898 A CA 2258898A CA 2258898 C CA2258898 C CA 2258898C
Authority
CA
Canada
Prior art keywords
molecules
release
reservoirs
reservoir
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002258898A
Other languages
French (fr)
Other versions
CA2258898A1 (en
Inventor
John T. Santini, Jr.
Michael J. Cima
Robert S. Langer
Achim M. Gopferich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CA2258898A1 publication Critical patent/CA2258898A1/en
Application granted granted Critical
Publication of CA2258898C publication Critical patent/CA2258898C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • CCHEMISTRY; METALLURGY
    • C25ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25FPROCESSES FOR THE ELECTROLYTIC REMOVAL OF MATERIALS FROM OBJECTS; APPARATUS THEREFOR
    • C25F7/00Constructional parts, or assemblies thereof, of cells for electrolytic removal of material from objects; Servicing or operating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0244Micromachined materials, e.g. made from silicon wafers, microelectromechanical systems [MEMS] or comprising nanotechnology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Microchips are provided, which control both the rate and time of release of multiple chemical substances and which allow for the release of a wide variety of molecules in either a continuous or pulsatile manner. In all of the preferred embodiments, a material that is impermeable to the drugs or other molecules to be delivered and the surrounding fluids is used as the substrate. Reservoirs are etched into the substrate using either chemical (wet) etching or ion beam (dry) etching techniques well-known in the field of microfabrication.
Hundreds to thousands of reservoirs can be fabricated on a single microchip using these techniques. A release system, which includes the molecules to be delivered, is inserted into the reservoirs by injection, inkjet printing or spin coating methods. Exemplary release systems include polymers and polymeric matrices, non-polymeric matrices, and other excipients or diluents. The physical properties of the release system control the rate of release of the molecules. The reservoirs can contain multiple drugs or other molecules in variable dosages. The filled reservoirs can be capped with materials that either degrade, dissolve, or allow the molecules to diffuse passively out of the reservoir over time or materials that, upon application of an electric potential, oxidize to form soluble compounds or ions that dissolve into the surrounding fluids. Release from an active device can be controlled by a preprogrammed microprocessor, remote control, or by biosensors.

Description

MICROCHIP DRUG DELIVERY DEVICES
Background of the Invention This invention relates to miniaturized drug delivery devices and more particularly, to controlled time and rate release mufti-welled drug delivery devices.
Drug delivery is an important aspect of medical treatment. The efficacy of many drugs is directly related to the way in which they are administered. Some therapies require that the drug be repeatedly administered to the patient over a long period of time. This makes the selection of a proper drug delivery method problematic. Patients often forget, are unwilling, or are unable to take their medication. Drug delivery also becomes problematic when the drugs are too potent for systemic delivery. Therefore, attempts have been made to design and fabricate a delivery device which is capable of the controlled, pulsatile or continuous release of a wide variety of molecules including, but not limited to, drugs and other therapeutics.
Controlled release polymeric devices have been designed to provide drug release over a period of time via diffusion of the drug out of the polymer and/or degradation of the polymer over the desired time period following administration to the patient. However, these devices are relatively simple.
U.S. Patent No. 5,490,962 to Cima, et al. discloses the use of three dimensional printing methods to make more complex devices which provide release over a desired time frame, of one or more drugs.
Although the general procedure for making a complex device is described, specific designs are not detailed.
U.S. Patent No. 4,003,379 to Ellinwood describes an implantable electromechanically driven device that includes a flexible retractable walled container, which receives medication from a storage area via an inlet and then dispenses the medication into the body via an outlet. U.S.
Patent No. 4,146,029 and U.S. Patent No. 3,692,027 to Ellinwood _2_ disclose self powered medication systems that have programmable miniaturized dispensing means. U.S. Patent No. 4,360,019 to Jassawalla discloses an implantable infusion device that includes an actuating means for delivery of the drug through a catheter. The actuating means includes a solenoid driven miniature pump. All of these devices include miniature power-driven mechanical parts that are required to operate in the body, i.e., they must retract, dispense, or pump. These are complicated and subject to breakdown. Moreover, due to complexity and size restrictions, they are unsuitable to deliver more than a few drugs or drug mixtures at a time.
It is therefore an object of the present invention to provide a simple to use and manufacture, dependable, mufti-welled delivery device for drugs and other molecules which can operate for weeks or years at a time.
It is another object of the present invention to provide such a device that allows delivery of drugs or other molecules in either a pulsatile or continuous manner.
It is yet another object of the present invention to provide such a device that allows the delivery to be controlled either passively or actively.
It is also an object of the present invention to provide such a device that can hold many different drugs or other molecules of varying dosages and is small enough to be implanted, injected or swallowed, if desired.
Summary of the Invention In one aspect of the invention there is provided a microchip device for storage and release of molecules including a substrate and at least two reservoirs provided in the substrate. Molecules for release are provided in the reservoirs and reservoir caps are positioned over the molecules. Release of the molecules from the reservoir is controlled by the disintegration of the reservoir cap or diffusion of the molecules through the reservoir cap.

-2a-The invention also provides a microchip device for the storage and release of molecules including a substrate and at least two discrete reservoirs provided in spaced positions across at least one surface of the substrate. A
discrete release system is loaded in each of the two reservoirs and includes molecules dispersed in a degradable matrix material or in a non-degradable matrix material. Release of the molecules from each reservoir is controlled by the disintegration of the matrix material or diffusion of the molecules from the matrix material.
Microchips for delivery of a wide variety of molecules are provided.
Microchips are miniaturized devices constructed using methods commonly applied to the manufacture of integrated circuits such as ultraviolet (UV) photolithography, reactive ion etching, and electron beam evaporation. The microchips provide control over the rate the molecules WO 98!00107 PCT/CTS97/11589 are released as well as the time at which release begins. The time of release can be controlled passively or actively.
In the preferred embodiments, a material which is impermeable to the surrounding fluids arid to the molecules to be delivered is used as the substrate. Examples of substrate materials include ceramics, semiconductors such as silicon, and degradable and non-degradable polymers. Reservoirs are etched into the substrate using either chemical (wet) etching or ion (dry) etching techniques commonly used in microfabrication. Hundreds to thousands of reservoirs can be created in this manner and contained in a single microchip. Typically, a release system containing, encapsulating, or consisting of the molecule to be delivered is inserted into the reservoirs by injection, inkjet printing, or other means. The release system controls the rate of release of the molecule. The rate of release is a function of the composition and IS structure of the release system. The device design makes it possible to fill the reservoirs with a release system in solid, liquid, or gel form.
Each of the reservoirs of a single microchip can contain different molecules and/or different amounts and concentrations, which can be released independently.
In a preferred embodiment, the reservoir cap enables passive timed release, not requiring a power source, of molecules. The reservoirs are capped with materials that degrade or dissolve at a known rate or have a known permeability (diffusion constant) for the molecules to be delivered.
Therefore, the degradation, dissolution or diffusion characteristics of the cap material determine the time at which the release of molecules in a particular reservoir begins. In effect, the microchip provides dual control of the release of molecules by selection of the release system {rate ' controller) and selection of the cap material (time controller, and in some cases, rate controller).
In another preferred embodiment, the reservoir cap enables active timed release, requiring a power source, of molecules. In this embodiment, the reservoir caps consist of a thin film of conductive material that is deposited over the reservoir, patterned to a desired geometry, and serves as an anode. Cathodes are also fabricated on the device with their size and placement dependent on the device's application , and method of electric potential control. Conductive materials capable of dissolving into solution or forming soluble compounds or ions upon the .
application of an electric potential, including metals such as copper, gold, silver, and zinc and some polymers, are used in the active timed release device. When an electric potential is applied between an anode and cathode, the conductive material of the anode above the reservoir oxidizes to form soluble compounds or ions that dissolve into solution, exposing the release system containing the molecules to be delivered to the surrounding fluids. Alternatively, the application of an electric potential can be used to create changes in local pH near the anode reservoir cap to allow normally insoluble ions or oxidation products to become soluble.
This would allow the reservoir to dissolve and expose the release system to the surrounding fluids. In either case, the molecules to be delivered are released into the surrounding fluids by diffusion out of or by degradation or dissolution of the release system. The frequency of release is controlled by incorporation of a miniaturized power source and microprocessor onto the microchip. Activation of any reservoir can be achieved by preprogramming the microprocessor, by remote control, or by a signal from a biosensor.
Description of the Drawings Figure 1 depicts a typical fabrication scheme for a passive delivery device.
Figure 2 depicts a typical fabrication scheme for an active delivery device.
Figure 3 depicts a typical device control circuitry flowsheet.
Figure 4 depicts a passive delivery device.
Figure 5 depicts an active delivery device.

Figure 6 depicts an active device including insulator overlayers.
Figures 7a-i are schematic views of several configurations of passive delivery devices.
Figures 8a-c are schematic views of several configurations of v 5 active delivery devices.
Detailed Description Microchip devices have been provided which can accurately deliver drugs and other molecules at defined rates and times according to the needs of the patient or other experimental system. As used herein, a "microchip" is a miniaturized device fabricated using methods commonly applied to the manufacture of integrated circuits such as ultraviolet (UV) photolithography, reactive ion etching, and electron beam evaporation, as described, for example, by S. Wolf and R.N. Tauber, Silicon Processing for the VLSI Era, Volume I - Process Technoloy , Lattice Press, Sunset Beach, CA, 1986; and R.C. Jaeger, Introduction to Microelectronic Fabrication, Volume V in the Modular Series on Solid State Devices, Addison-Wesley, Reading, MA, 1988. The microchips provide control over the rate the molecules are released as well as the time at which release begins. The time of release can be controlled passively or actively. The microchip fabrication procedure allows the manufacture of devices with primary dimensions (length of a side if square or rectangular, or diameter if circular) ranging from a few millimeters to several centimeters. A typical device thickness is 300 Vim. However, the thickness of the device can vary from approximately 10 ~.m to several millimeters. Changing the device thickness affects the maximum number of reservoirs that may be incorporated onto a microchip and the volume of each reservoir. In vivo applications of the device would typically require devices having a primary dimension of 2 cm or smaller. Devices for in vivo applications are small enough to be swaIlored or implanted using minimally invasive procedures. Smaller in vivo devices {on the order of a millimeter) can be implanted using a catheter or other injectable means. Devices for in vitro applications have fewer size restrictions and, if necessary, can be made much larger than the dimension ranges for in vivo devices.
MATERIALS FOR DEVICE FABRICATION
Each device consists of a substrate, reservoirs, and a release system containing, enclosing, or layered with the molecules to be delivered. Devices which control the release time of the molecules may include reservoir caps. Active devices may include control circuitry and a power source.
IO The substrate The substrate contains the etched or machined reservoirs and serves as the support for the microchip. Any material which can serve as a support, is suitable for etching or machining, and is impermeable to the molecules to be delivered and to the surrounding fluids, for example, IS water, blood, electrolytes or other solutions, may be used as a substrate.
Biocompatibiiity of the substrate material is preferred, but not required.
For in vivo applications, non-biocompatible materials may be encapsulated in a biocompatible material, such as poly(ethyiene glycol) or polytetrafluoroethylene-like materials, before use. One example of a 20 strong, non-degradable, easily etched substrate that is impermeable to the molecules to be delivered and the surrounding fluids is silicon. In another embodiment, the substrate is made of a strong material that degrades or dissolves over a period of time into biocompatible components. This embodiment is preferred for in vivo applications where the device is 25 implanted and physical removal of the device at a Later time is not feasible or recommended, for example, brain implants. An example of a class of strong, biocompatible materials are the poly(anhydride-co-imides), discussed by K.E. Uhrich et al., "Synthesis and characterization of degradable poly(anhydride-co-imides)", Macromolecules, 1995, 28, 2184-30 93.

Release system The molecules to be delivered may be inserted into the reservoirs in their pure form, as a liquid solution or gel, or they may be encapsulated within or by a release system. As used herein, "release system" includes both the situation where the molecules are in pure form, as either a solid or liquid, or are in a matrix formed of degradable material or a material which releases incorporated molecules by diffusion out of or disintegration of the matrix. The molecules can be sometimes contained in a release system because the degradation, dissolution or diffusion properties of the release system provide a method for controlling the release rate of the molecules. The molecules can be homogeneously or heterogeneously distributed within the release system. Selection of the release system is dependent on the desired rate of release of the molecules. Both non-degradable and degradable release systems can be used for delivery of molecules. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar. Release systems may be natural or synthetic, although synthetic release systems are preferred due to the better characterization of release profiles. The release system is selected based on the period over which release is desired, generally in the range of at least three to twelve months for in vivo applications. In contrast, release times as short as a few seconds may be desirable for some in vitro applications. In some cases, continuous (constant) release from a reservoir may be most useful. In other cases, a pulse (bulk) release from a reservoir may provide more effective results. Note that a single pulse from one reservoir can be transformed into pulsatile release by using multiple reservoirs. It is also - possible to incorporate several layers of a release system and other materials into a single reservoir to achieve pulsatile delivery from a single reservoir . Continuous release can be achieved by incorporating a release system that degrades, dissolves, or allows diffusion of molecules through WO 98/OO1U7 PCT/LTS97/ii589 _g_ it over an extended period of time. In addition, continuous release can be stimulated by releasing several pulses of molecules in quick succession.
The release system material can be selected so that molecules of various molecular weights are released from a reservoir by diffusion out or through the material or degradation of the material. Biodegradable polymers, bioerodible hydrogels, and protein delivery systems are preferred for release of molecules by diffusion, degradation, or dissolution. In general, these materials degrade or dissolve either by .
enzymatic hydrolysis or exposure to water in vivo or in vitro, or by surface or bulk erosion. Representative synthetic, biodegradable polymers include: poly(amides) such as poly(amino acids) and poly(peptides);
polyesters) such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides};
poly(orthoesters); poly(carbonates); and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.
Representative synthetic, non-degradable polymers include:
poly(ethers) such as polyethylene oxide), polyethylene glycol), and poly(tetramethylene oxide); vinyl polymers - poly(acrylates) and poly(methacrylates) such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others such as polyvinyl alcohol), polyvinyl pyrolidone), and polyvinyl acetate}; poly(urethanes);
cellulose and its derivatives such as alkyl, hydroxyalkyI, ethers, esters, nitrocellulose, and various cellulose acetates; poiy(siloxanes); and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.

WO 98/00107 P'CT/US97/11589 Molecules to be released Any natural or synthetic, organic or inorganic molecule or mixture thereof can be delivered. In one embodiment, the microchip is used to deliver drugs systemically to a patient in need thereof. In another embodiment, the construction and placement of the microchip in a patient enables the localized release of drugs that may be too potent for systemic delivery. As used herein, drugs are organic or inorganic molecules, including proteins, nucleic acids, polysaccharides and synthetic organic molecules, having a bioactive effect, for example, anaesthetics, vaccines, I0 chemotherapeutic agents, hormones, metabolites, sugars, immunomodulators, antioxidants, ion channel regulators, and antibiotics.
The drugs can be in the form of a single drug or drug mixtures and can include pharmaceutically acceptable carriers. In another embodiment, molecules are released in vitro in any system where the controlled release IS of a small (milligram to nanogram) amount of one or more molecules is required, for example, in the fields of analytic chemistry or medical diagnostics. Molecules can be effective as pH buffering agents, diagnostic agents, and reagents in complex reactions such as the polymerase chain reaction or other nucleic acid amplification procedures.
20 Reservoir caps In the passive timed release drug delivery devices, the reservoir caps are formed from a material that degrades or dissolves over time, or does not degrade or dissolve but is permeable to the molecules to be delivered. These materials are preferably polymeric materials. Materials 25 can be selected for use as reservoir caps to give a variety of degradation rates or dissolution rates or permeabilities to enable the release of molecules from different reservoirs at different times and, in some cases, - different rates. To obtain different release times (amounts of release time delay), caps can be formed of different polymers, the same polymer with 30 different degrees of crosslinking, or a UV polymerizable polymer. In the latter case, varying the exposure of this polymer to UV light results in varying degrees of crosslinking and gives the cap material different WO 98/00107 I'CT/LTS97l11589 diffusion properties or degradation or dissolution rates. Another way to obtain different release times is by using one polymer, but varying the thickness of that polymer. Thicker films of some polymers result in , delayed release time. Any combination of polymer, degree of crosslinking, or polymer thickness can be modified to obtain a specific release time or rate. In one embodiment, the release system containing the molecules to be delivered is covered by a degradable cap material which is nearly impermeable to the molecules. The time of release of the molecules from the reservoir will be limited by the time necessary for the cap material to degrade or dissolve. in another embodiment, the cap material is non-degradable and is permeable to the molecules to be delivered. The physical properties of the material used, its degree of crosslinking, and its thickness will determine the time necessary for the molecules to diffuse through the cap material. If diffusion out of the release system is limiting, the cap material delays the onset of release. If diffusion through the cap material is Limiting, the cap material determines the release rate of the molecules in addition to delaying the onset of release.
In the active timed release devices, the reservoir caps consist of a thin film of conductive material that is deposited over the reservoir, patterned to a desired geometry, and serves as an anode. Cathodes are also fabricated on the device with their size and placement dependent on the device's application and method of electric potential control. The anode is defined as the electrode where oxidation occurs. Any conductive material capable of dissolving into solution or forming soluble ions or oxidation compounds upon application of an electric potential can be used for the fabrication of the anodes and cathodes. In addition, materials that normally form insoluble ions or oxidation products in response to an electric potential can be used if, for example, Local pH changes near the anode cause these oxidation products to become soluble. Examples of suitable reservoir cap materials include metals such as copper, gold, silver, and zinc, and some polymers, as described, for example, by LC.

Kwon et al. , "Electrically erodible polymer gel for controlled release of drugs", Nature, 1991, 354, 291-93; and Y.H. Bae et al., "Pulsatile drug release by electric stimulus", ACS Symposium Series, 1994, 545, 98-110.
Device packaging, control circuitry, and power source Microelectronic device packages are typically made of an insulating or dielectric material such as aluminum oxide or silicon nitride.
Their purpose is to allow all components of the device to be placed in close proximity and to facilitate the interconnection of components to power sources and to each other. For in vivo applications of the delivery device, the entire package, including all components (i.e. the device, the microprocessor, and the power source), are coated or encapsulated in a biocompatible material such as polyethylene glycol) or polytetrafluoroethylene-like materials. The materials requirements for in vitro applications may be less stringent and depend on the particular situation.
The control circuitry consists of a timer, a demultiplexer, a microprocessor, and a input source, for example, a memory source, a signal receiver, or a biosensor. The timer and demultiplexer circuitry can be designed and incorporated directly onto the surface of the microchip during electrode fabrication. The criteria for selection of a microprocessor are small size, low power requirement, and the ability to translate the output from memory sources, signal receivers, or biosensors into an address for the direction of power through the demultiplexer to a specific reservoir on the delivery device. Selection of a source of input to the microprocessor such as memory sources, signal receivers, or biosensors depends on the delivery device's particular application and whether device operation is preprogrammed, controlled by remote means, or controlled by feedback from its environment (i.e. biofeedback).
The criteria for selection of a power source are small size, sufficient power capacity, ability to be integrated into the control circuitry, the ability to be recharged, and the length of time before recharging is necessary. Several lithium-based, rechargeable microbatteries have been described by S.D. Jones and J.R. Akridge, "Development and performance of a rechargeable thin-film solid-state microbattery", Journal of Power Sources, 1995, 54, 63-67; and J.B.
Bates et al. , "New amorphous thin-film lithium electrolyte and rechargeable microbattery", IEEE 35'" International Power Sources Symposium, 1992, 337-39. These batteries are typically only ten microns thick and occupy 1 em2 of area. One or more of these batteries can be incorporated directly onto the delivery device.
METHODS OF DEVICE FABRICATION
Fabrication of the reservoirs Devices are manufactured using methods known to those skilled in the art, reviewed, for example, by Wolf et al. (1986); and Jaeger (1988);
Kwon et al. (1991).
In a preferred method of microchip manufacture, depicted in Figures i and 2, passive and active devices, respectively, fabrication begins by depositing and photolithographically patterning a material, typically an insulating or dielectric material, onto the substrate to serve as an etch mask during reservoir etching. Typical insulating materials for use as a mask include silicon nitride, silicon dioxide, and some polymers, such as polyimide. In a preferred embodiment, a thin film (approximately 1000-3000 ~) of amorphous silicon nitride (SiNx) is deposited on both sides of a silicon wafer 30/300 by Plasma Enhanced Chemical Vapor Deposition (PECVD). Alternatively, a low stress, silicon-rich nitride can be deposited in a Vertical Tube Reactor (VTR), or a stoichiometric, polycrystalline nitride can be deposited by Low Pressure Chemical Vapor Deposition (LPCVD). Reservoirs are patterned into the silicon nitride film on one side of the wafer 32/320 by ultraviolet photolithography and either plasma etching or a chemical etch consisting of hot phosphoric acid. The patterned silicon nitride serves as an etch mask for the chemical etching of the exposed silicon 34/340 by a concentrated potassium hydroxide solution (approximately 38.5 ~ wt. at a temperature of 80-85°C). Alternatively, the reservoirs can be etched into the substrate WO 98/00107 PCT/LTS9711i589 by dry etching techniques such as reactive ion etching or ion beam etching. These techniques are commonly used in the fabrication of microelectronic devices, as reviewed, for example, by Wolf et al. (1986) and Jaeger (1988). Use of these microfabrication techniques allows the incorporation of hundreds to thousands of reservoirs on a single microchip. In a passive device, the reservoirs may be as little as one ,um apart. In an active device, the distance between the reservoirs may be slightly larger (approximately 10-15 gum) due to the space occupied by the electrodes on or near each reservoir. Reservoirs can be made in nearly any shape and depth, and need not pass completely through the substrate.
In a preferred embodiment, the reservoirs etched into a {100) silicon substrate by potassium hydroxide are in the shape of a square pyramid having side walls sloped at 54° and pass completely through the substrate (approximately 300 ~.m) to the silicon nitride film on the other side of the substrate, forming a SiN4 membrane. {Here, the silicon nitride film serves as a potassium hydroxide etch stop. ) The pyramidal shape allows easy filling of the reservoirs through the large opening of the reservoir (approximately 500 ~,m by 500 ~,m) on the patterned side of the substrate, release through the small opening of the reservoir (approximately 30 lcm by 30 ,um) on the other side of the substrate, and provides a large cavity inside the device for storing the drugs or other molecules to be delivered.
Fabrication of passive timed release reservoir caps In the fabrication of passive timed release microchips, the reservoir cap material is injected with a micro-syringe 36a, printed with an inkjet printer cartridge, or spin coated 36b into a reservoir having the thin film of insulating mask material still present over the small opening of the reservoir. If injection or inkjet printing methods are used, cap formation is complete after the material is injected or printed into the reservoir 38a and does not require further. processing. If spin coating is used, the cap material is planarized by multiple spin coatings 36b. The surface of the film is then etched by a plasma, an ion beam, or chemical etchant until the desired cap thickness is obtained 38b. In a preferred embodiment, the insulating material used is silicon nitride and the cap material is printed into the reservoir with an inkget cartridge filled with a solution of the cap material.
Reservoir caps control the time at which molecules are released from the reservoirs. Each reservoir cap can be of a different thickness or have different physical properties to vary the time at which each release system containing the molecules is exposed to the surrounding fluids.
Injection, inkjet printing, and spin coating are the preferred methods of reservoir filling and any of these methods may be used to fill reservoirs, regardless of the reservoir's shape or size. However, injection and inkjet printing are the preferred methods of filling deep (greater than 10 p,m) reservoirs or reservoirs with large openings (greater than 100 hem) . For example, to obtain different cap thicknesses using injection, different amounts of cap material are injected or printed directly into each individual reservoir. Spin coating is the preferred method of filling shallow (less than 10 ,um) reservoirs, reservoirs that do not pass completely through the substrate, or reservoirs with small (less than 100 ~cm} openings. Variation in cap thickness or material by spin coating can be achieved by a repeated, step-wise process of spin coating, masking selected reservoirs, and etching. For example, to vary cap thickness with spin coating, the cap material is spin coated over the entire substrate.
Spin coating is repeated, if necessary, until the material is nearly planarized. A mask material such as photoresist is patterned to cover the cap material in all the reservoirs except one. Plasma, ion beam, or chemical etchant are used to etch the cap material in the exposed reservoir to the desired thickness. The photoresist is then removed from the substrate. The process is repeated as a new layer of photoresist is deposited and patterned to cover the cap material in all the reservoirs except one (the exposed reservoir is not the same one already etched to its desired thickness). Etching of the exposed cap material in this reservoir continues until the desired cap thickness is obtained. This process of depositing and patterning a mask material such as photoresist, etching, and mask removal can be repeated until each reservoir has its own unique cap thickness. The techniques, UV photolithography, plasma or ion beam etching, etc., are well known to those skilled in the field of microfabrication.
Although injection, inkjet printing and spin coating are the preferred methods of cap fabrication, it is understood that each reservoir can be capped individually by capillary action, by pulling or pushing the material into the reservoir using a vacuum or other pressure gradient, by melting the material into the reservoir, by centrifugation and related processes, by manually packing solids into the reservoir, or by any combination of these or similar reservoir filling techniques.
Once a cap fabrication method is selected, additional methods for controlling the time of release of molecules from a reservoir can be utilized. Two non-Limiting examples include either UV polymerizable polymers or the layering of release system and cap materials. First, if the reservoir caps are made of either an injected, inkjet printed or spin coated UV polymerizable polymer, each cap can be exposed to a different intensity of UV light to give varying degrees of crosslinking and therefore, different degradation or dissolution rates for degradable caps or different perrneabilities to the molecules for non-degradable caps.
Second, layers of cap material, both degradable and non-degradable, can be inserted between Layers of the release system containing the molecules to be delivered by injection, inkjet printing, spin coating, or selective crosslinking. These and other similar methods allow complex release profiles (i.e. pulsatile delivery at irregular time intervals} to be achieved from a single reservoir.
If desired, a passive timed release device can be fabricated without reservoir caps. The rate of release of the molecules is thus solely controlled by the physical and material properties of the release system containing the molecule to be delivered.

WO 98/001.07 PCT/U597/11589 Fabrication of active timed release reservoir caps In a preferred embodiment, photoresist is patterned in the form of electrodes on the surface of the substrate having the reservoirs covered by , the thin membrane of insulating or dielectric material. The photoresist is developed such that the area directly over the covered opening of the .
reservoir is left uncovered by photoresist and is in the shape of an anode.
A thin film of conductive material capable of dissolving into solution or forming soluble ions or oxidation compounds upon the application of an electric potential is deposited over the entire surface using deposition techniques such as chemical vapor deposition, electron or ion beam evaporation, sputtering, spin coating, and other techniques known in the art. Exemplary materials include metals such as copper, gold, silver, and zinc and some polymers, as disclosed by Kwon et al. (I991) and Bae et al. (1994). After film deposition, the photoresist is stripped from the substrate. This removes the deposited film, except in those areas not covered by photoresist (lift-off technique). This leaves conducting material on the surface of the substrate in the form of electrodes 360. An alternative method involves depositing the conductive material over the entire surface of the device, patterning photoresist on top of the conductive film using LTV or infrared (IR) photolithography, so that the photoresist lies over the reservoirs in the shape of anodes, and etching the unmasked conductive material using plasma, ion beam, or chemical etching techniques. The photoresist is then stripped, leaving conductive film anodes covering the reservoirs. Typical film thicknesses of the conductive material may range from 0.05 to several microns. The anode serves as the reservoir cap and the placement of the cathodes on the device is dependent upon the device's application and method of electric potential control.
An insulating or dielectric material such as silicon oxide (SiOX) or silicon nitride (SiNX) is deposited over the entire surface of the device by methods such as chemical vapor deposition (CVD), electron or ion beam evaporation, sputtering, or spin coating. Photoresist is patterned on top of the dielectric to protect it from etching except on the cathodes and the portions of the anodes directly over each reservoir 380. The dielectric material can be etched by plasma, ion beam, or chemical etching techniques. The purpose of this film is to protect the electrodes from corrosion, degradation, or dissolution in all areas where electrode film is not necessary for release.
The electrodes are positioned in such a way that when an electric between an anode and a cathode, the unprotected (not covered by dielectric) portion of the anode reservoir cap oxidizes to form soluble compounds or ions that dissolves into solution, exposing the release system containing the molecules to the surrounding fluids. The molecules are released from the reservoir at a rate dependent upon the degradation or dissolution rate of a degradable release system or the rate of diffusion of the molecules out of or through a non-degradable release system.
Removal of the insulator membrane (reservoir etch stop) The thin membrane of insulating or dielectric material covering the reservoir used as a mask and an etch stop during reservoir fabrication must be removed from the active timed release device before filling reservoir 400 and from the passive timed release device (if the reservoir extends completely through the substrate) after filling reservoir 44. The film may be removed in two ways. First, the film can be removed by an ion beam or reactive ion plasma. In a preferred embodiment, the silicon nitride film used as the insulating material can be removed by a reactive ion plasma composed of oxygen and fluorine containing gases such as CHF3 or CF4. Second, the film can be removed by chemical etching.
For example, buffered hydrofluoric acid (BHF or BOE) can be used to etch silicon dioxide and hot phosphoric acid can be used to etch silicon nitride.

WO 98!00107 PCT/US97/11589 Reservoir filling The release system containing the molecules for delivery is inserted into the large opening of the reservoir by injection, inkjet , printing or spin coating 40a/40b/400. Each reservoir can contain a different molecule and dosage. Similarly, the release kinetics of the molecule in each reservoir can be varied by the choice of the release system and cap materials. In addition, the mixing or layering of release system and cap materials in each reservoir can be used to tailor the release kinetics to the needs of a particular application.
The distribution over the microchip of reservoirs filled With the release system containing the molecules to be delivered can vary depending on the medical needs of the patient or other requirements of the system. For applications in drug delivery, for example, the drugs in each of the rows can differ from each other. One row may contain a hormone I5 and another row may contain a metabolite. Also, the release system can differ within each row to release a drug at a high rate from one reservoir and a slow rate from another reservoir. The dosages can also vary within each row. For those devices having deep (greater than 10 ,gym) reservoirs or reservoirs with large (greater than 100 /cm) openings, differences in reservoir loading can be achieved by injection or inkjet printing of different amounts of material directly into each reservoir. Variation between reservoirs is achieved in devices having shallow (less than 10 um) reservoirs, reservoirs that do not pass completely through the substrate, or reservoirs with small (less than 100 ~cm) openings by a repeated, step-wise process of masking selected reservoirs, spin coating, and etching, as described above regarding the fabrication by spin coating of passive timed release reservoir caps. Preferably, the release system and molecules to be delivered are mixed before application to the ' reservoirs. Although injection, inkjet printing and spin coating are the preferred methods of filling reservoirs, it is understood that each reservoir can be filled individually by capillary action, by pulling or pushing the material into the reservoir using a vacuum or other pressure gradient, by melting the material into the reservoir, by centrifugation and related processes, by manually packing solids into the reservoir, or by any combination of these or similar reservoir filling techniques.
Device packaging, control circuitry, and power source _ S The openings through which the reservoirs of passive and active devices are filled are sealed by wafer bonding or with a waterproof epoxy or other appropriate material impervious to the surrounding fluids 44/440.
For in vitro applications, the entire unit, except for the face of the device containing the reservoirs and electrodes, is encased in a material appropriate for the system. For in vivo applications, the unit would be encapsulated in a biocornpatibie material such as polyethylene glycol) or polytetrafluoroethylene.
The mechanism for release of molecules by the active timed release device does not depend on multiple parts fitted or glued together which must retract or dislodge. Control of the time of release of each reservoir can be achieved by a preprogrammed microprocessor, by remote control, by a signal from a biosensor, or by any combination of these methods, as shown schematically in Figure 3. First, a microprocessor is used in conjunction with a source of memory such as programmable read only memory (PROM), a timer, a demultiplexer, and a power source such as a microbattery, such as is described, for example, by Jones et al.
(1995) and Bates et al. (1992). The release pattern is written directly into the PROM by the user. The PROM sends these instructions to the microprocessor. When the time fox release has been reached as indicated by the timer, the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer. The demultiplexer sends an input, such as an electric potential, to the reservoir addressed by the microprocessor. A microbattery provides the power to operate the PROM, timer, and microprocessor, and provides the electric potential input that is directed to a particular reservoir by the demultiplexer. The manufacture, size, and location of each of these components is dependent upon the requirements of a particular application. In a preferred embodiment, the memory, timer, microprocessor, and demultiplexer circuitry is integrated directly onto the surface of the chip. The rnicrobattery is attached to the other side of the chip and is connected to the device circuitry by vias or thin Wires.
However, in some cases, it is possible to use separate, prefabricated, -component chips for memory, timing, processing, and demultipIexing.
These are attached to the backside of the miniaturized delivery device with the battery. The size and type of prefabricated chips used depends on the overall dimensions of the delivery device and the number of reservoirs. Second, activation of a particular reservoir by the application of an electric potential can be controlled externally by remote control.
Much of the circuitry used for remote control is the same as that used in the preprogrammed method. The main difference is that the PROM is replaced by a signal receiver. A signal such as radio waves, low power laser, or ultrasound is sent to the receiver by an external source, for example, computers or ultrasound generators. The signal is sent to the microprocessor where it is translated into a reservoir address. Power is then directed through the demultiplexer to the reservoir having the appropriate address. Third, a biosensor is integrated into the microchip to detect molecules in the surrounding fluids. When the concentration of the molecules reaches a certain level, the sensor sends a signal to the microprocessor to activate one or more reservoirs. The microprocessor directs power through the demultipIexer to the particular reservoir(s).
Electric Potential Control Methods The reservoir caps of an active device are anodes that oxidize to form soluble compounds and ions when a potential is applied between the anode and a cathode. For a given electrode material and electrolyte, there exists a range of electric potentiais over which these oxidation reactions are thermodynamically and kinetically favorable. In order to reproducibly oxidize and open the device's reservoir caps, the anode potential must be maintained in this potential range.

There exist two primary control methods for maintaining an electrode within a specific potential range. The first method is called potentiostatic control. As the name indicates, the potential is kept constant during reservoir activation. Control of the potential is typically r 5 accomplished by incorporating a third electrode into the system that has a known, constant potential, called a reference electrode. The reference electrode can take the form of an external probe whose tip is placed within one to three mm of the anode surface. The potential of the anode is measured and controlled with respect to the known potential of a IO reference electrode such as a saturated calomel electrode (SCE). In a preferred embodiment of potentiostatic control, a thin film reference electrode and potential feedback controller circuitry could be fabricated directly onto the surface of the microchip. For example, a microfabricated Ag/AgCI reference electrode integrated with a microchip 15 device would enable the device to maintain the anode potential of an activated reservoic within the oxidation regime until the reservoir was completely opened. The second method is called galvanostatic control.
As the name indicates, the current is kept constant during reservoir activation. One drawback to this method of control is that there is more 20 than one stable potential for a given current density. However, if the current density versus potential behavior is well characterized for the microchip device in a particular electrolyte system, the current density that will maintain the anode in teh oxidation regime will be known. In this case, the galvanostatic method of potential control would be 25 preferable to the potentiostatic control, because galvanostatic control does not require a reference electrode.
MICROCHIP APPLICATIONS
Passive and active microchip devices have numerous in vitro and in vivo applications. The microchip can be used in vitro to deliver small, 30 controlled amounts of chemical reagents or other molecules to solutions or reaction mixtures at precisely controlled times and rates. Analytical chemistry and medical diagnostics are examples of fields where the microchip delivery device can be used. The microchip can be used in vivo as a drug delivery device. The microchips can be implanted into a patient, either by surgical techniques or by injection, or can be swallowed. The microchips provide delivery of drugs to animals or persons who are unable to remember or be ambulatory enough to take -medication. The microchips further provide delivery of many different drugs at varying rates and at varying times of delivery.
The present invention will be further understood by reference to the following non-limiting examples.
Example 1: Microchip with passive timed drug release.
A passive timed release device, microchip 10 is shown in Figure 4. Microchip 10 is formed from substrate 14. Reservoirs I6 are etched into substrate 14. Positioned in reservoirs 16 is a release system containing molecules I8 for delivery. The reservoirs are capped with reservoir caps 12. The release system and the molecules for delivery 18 can vary between rows 20a, 20b, 20c, and within reservoirs of each row.
Microchip 10 can be inserted into solution for in vitro applications or be implanted in a selected part of the body or swallowed for in vivo applications and left to operate without requiring further attention. When exposed to the surrounding fluids, reservoir caps 12 will degrade, dissolve or become permeable to the release system containing molecules for delivery 18.
Figures 7a-i depict several additional possible configurations for passive delivery devices.
Example 2: Microchip with active controlled time release.
A drug delivery device that provides active timed release is shown as microchip 100 in Figure 5. Microchip 100 is similar to microchip 10 except that microchip 100 contains electrodes that provide for active timed release. Microchip 100 is formed from substrate 160, release system containing molecules 180 for delivery, anode reservoir caps 120, and cathodes 140. Preferably, microchip 100 further includes an input source, a microprocessor, a timer, a demultiplexer, and a power source (not shown). The power source provides energy to drive the reaction between selected anodes and cathodes. Upon application of a small potential between an anode and cathode, electrons pass from the anode to the cathode through the external circuit causing the anode material to oxidize and form soluble compounds or ions that dissolve into the surrounding fluids, exposing the release system containing the molecules for delivery 180 to the surrounding fluids. The microprocessor directs power to specific electrode pairs through a demultiplexer as directed by a PROM, remote control, or biosensor.
Figure 6 is a schematic of a second embodiment of a microchip 200 from from substrate 260 actively releasing drug 280 from the device upon application of an electric potential between an anode and cathode, which, unlike the device in Figure 5, includes an insulator overlayer.
Figures 8a-c depicts three additional possible configurations for active delivery devices.

Claims (38)

We claim:
1. A microchip device for the storage and release of molecules comprising:
a substrate;
at least two reservoirs provided in the substrate;
molecules for release, the molecules being provided in the at least two reservoirs; and reservoir caps positioned over the molecules, wherein release of the molecules from the reservoir is controlled by the disintegration of the reservoir cap or diffusion of the molecules through the reservoir cap.
2. The device of claim 1, wherein the reservoir cap is impermeable to the molecules and disintegration of the reservoir cap is actively controlled.
3. The device of claim 2, further comprising a cathode, a microprocessor, and a power source, wherein the reservoir cap is an anode, and wherein upon application of an electric potential between the cathode and the anode, the reservoir cap oxidizes, dissolves, and disintegrates to release the molecules.
4. The device of claim 2 or 3, wherein release of the molecules from one of the reservoirs is controlled by a signal from a biosensor, by remote control, or by a preprogrammed microprocessor.
5. The device of any one of claims 1-4, wherein the substrate comprises silicon.
6. The device of any one of claims 1-5, wherein the reservoir cap comprises a metal film.
7. The device of claim 1, wherein the disintegration of the reservoir cap is passively controlled.
8. The device of claim 7, wherein the release of the molecules from the reservoirs is controlled by the in vivo disintegration of the reservoir cap.
9. The device of claim 1 or 8, wherein the reservoir cap comprises a polymer.
10. The device of any one of claims 1-9, wherein the molecules for release are dispersed in a matrix material.
11. The device of claim 10, wherein the matrix material comprises a polymer.
12. The device of any one of claims 1-11, wherein the molecules for release comprise at least one drug.
13. A microchip device for the storage and release of molecules comprising:
a substrate;
at least two discrete reservoirs provided in spaced positions across at least one surface of the substrate; and a discrete release system loaded in each of the at least two reservoirs, the release system including molecules dispersed in a degradable matrix material or in a non-degradable matrix material, wherein release of the molecules from each reservoir is controlled by the disintegration of the matrix material or diffusion of the molecules from the matrix material.
14. The device of claim 13, wherein the molecules for release are drug molecules dispersed in a degradable matrix material and the release of the drug molecules from the reservoirs is controlled by the in vivo dissolution, enzymatic hydrolysis, or erosion of the matrix material.
15. The device of claim 14, wherein the matrix material comprises one or more hydrogels or biodegradable polymers.
16. The device of claim 15, wherein said one or more biodegradable polymers are selected from poly(amides), poly(esters), poly(anhydrides), poly(orthoesters), poly(carbonates), copolymers thereof, or mixtures thereof.
17. The device of claim 15, wherein said one or more biodegradable polymers are selected from poly(lactic acids), poly(glycolic acids), poly(lactic-co-glycolic acids), poly(caprolactones), or mixtures thereof.
18. The device of claim 13, wherein the molecules for release are drug molecules dispersed in a non-degradable matrix material and the release of the drug molecules from the reservoirs is controlled by the in vivo diffusion of the drug molecules from the matrix material.
19. The device of claim 18, wherein the matrix material comprises one or more hydrogels or synthetic polymers.
20. The device of claim 19, wherein said one or more synthetic polymers are selected from poly(ethers), poly(acrylates), poly(methacrylates), poly(vinyl pyrolidones), poly(vinyl acetates), poly(urethanes), celluloses, cellulose acetates, and poly(siloxanes).
21. The device of any one of claims 13-20, further comprising at least two discrete reservoir caps, each reservoir cap covering one of the at least two reservoirs, and further controlling release of the molecules from the reservoirs by the disintegration of the reservoir cap or diffusion of the molecules through the reservoir cap.
22. The device of any one of claims 1-12 and 21, wherein the reservoir cap is degradable and comprises a material that disintegrates in vivo by dissolution, enzymatic hydrolysis, or erosion.
23. The device of any one of claims 1-12 and 21, wherein the reservoir cap is non-degradable and permeable to the molecules.
24. The device of any one of claims 21-23, wherein one of the reservoir caps is formed of a first material and the other of the at least two reservoir caps is formed of a second material, wherein the first material has a different disintegration rate in vivo or different permeability to the molecules compared to the second material.
25. The device of any one of claims 21-24, wherein one of the reservoir caps has a first thickness and the other of the at least two reservoir caps has a second, greater thickness.
26. The device of any one of claims 21-25, wherein at least one of the discrete reservoir caps comprises one or more synthetic polymers.
27. The device of any one of claims 1-26, wherein the molecules comprise one or more therapeutic agents selected from anesthetics, chemotherapeutic agents, hormones, immunomodulators, ion channel regulators, and antibiotics.
28. The device of any one of claims 1-27, wherein the molecules comprise drug molecules and the dose of drug molecules in one of the at least two reservoirs is different from the dose of drug molecules in the other of the at least two reservoirs.
29. The device of any one of claims 1-28, wherein the kinetics of release of the molecules from one of the at least two reservoirs is different from the kinetics of release of the molecules from the other of the at least two reservoirs.
30. The device of any one of claims 1-29, wherein the molecules comprise drug molecules and a first drug is in one of the at least two reservoirs and a second, different drug is in the other of the at least two reservoirs.
31. The device of any one of claims 1-30, wherein at least one of the reservoirs comprises two or more layers of the release system.
32. The device of claim 31, wherein a first drug is contained in a first layer of the two or more layers, and a second drug is contained in a second layer of the two or more layers.
33. The device of any one of claims 1-32, wherein at least one of the reservoirs comprises:
at least two layers of a release system comprising a drug, and at least one layer of a degradable or soluble material which does not comprise any drug and which is disposed between the at least two layers of a release system comprising the drug.
34. The device of any one of claims 1-33, wherein release of the molecules from the device is in pulsatile manner.
35. The device of any one of claims 1-34, comprising at least two rows of the at least two reservoirs in an array in the device.
36. The device of claim 35, wherein release across the substrate surface differs in the type of molecules released or in the release kinetics.
37. The device of any one of claims 1-36, which is adapted for implantation into a patient.
38. The device of claim 1, which is made by a process comprising the steps of:

depositing and patterning a material on a substrate, the material being an etch mask;
etching a plurality of reservoirs in the substrate;
filling the reservoirs with a composition comprising the molecules for release;
and capping the reservoirs with a cap material which is selectively permeable to the molecules, a cap material which disintegrates to release the molecules, or a combination thereof.
CA002258898A 1996-07-02 1997-07-02 Microchip drug delivery devices Expired - Lifetime CA2258898C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US675375 1996-07-02
US08/675,375 US5797898A (en) 1996-07-02 1996-07-02 Microchip drug delivery devices
PCT/US1997/011589 WO1998000107A2 (en) 1996-07-02 1997-07-02 Microchip drug delivery devices

Publications (2)

Publication Number Publication Date
CA2258898A1 CA2258898A1 (en) 1998-01-08
CA2258898C true CA2258898C (en) 2005-01-11

Family

ID=24710206

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002258898A Expired - Lifetime CA2258898C (en) 1996-07-02 1997-07-02 Microchip drug delivery devices

Country Status (10)

Country Link
US (2) US5797898A (en)
EP (1) EP0914092B1 (en)
JP (2) JP2000513725A (en)
AT (1) ATE216219T1 (en)
CA (1) CA2258898C (en)
DE (1) DE69712063T2 (en)
DK (1) DK0914092T3 (en)
ES (1) ES2176768T3 (en)
PT (1) PT914092E (en)
WO (1) WO1998000107A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface

Families Citing this family (524)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6861571B1 (en) * 1994-11-28 2005-03-01 The Procter & Gamble Company Article having a lotioned topsheet
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
DE19736520A1 (en) * 1997-08-22 1999-02-25 Lohmann Therapie Syst Lts New adhesive plaster containing electronic information
US6485462B1 (en) 1997-08-27 2002-11-26 Science Incorporated Fluid delivery device with heat activated energy source
US20030036746A1 (en) * 2001-08-16 2003-02-20 Avi Penner Devices for intrabody delivery of molecules and systems and methods utilizing same
CN1089922C (en) * 1998-01-15 2002-08-28 英业达股份有限公司 Cartoon interface editing method
US6610440B1 (en) * 1998-03-10 2003-08-26 Bipolar Technologies, Inc Microscopic batteries for MEMS systems
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7179289B2 (en) 1998-03-30 2007-02-20 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) * 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6908770B1 (en) 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6872187B1 (en) 1998-09-01 2005-03-29 Izex Technologies, Inc. Orthoses for joint rehabilitation
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
EP1113804A2 (en) * 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
WO2000034461A2 (en) 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US7914442B1 (en) 1999-03-01 2011-03-29 Gazdzinski Robert F Endoscopic smart probe and method
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
EP1169114B1 (en) 1999-03-12 2006-02-08 Microscent, LLC. Methods and apparatus for localized delivery of scented aerosols
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
US7416537B1 (en) 1999-06-23 2008-08-26 Izex Technologies, Inc. Rehabilitative orthoses
SE9902474D0 (en) * 1999-06-30 1999-06-30 Amersham Pharm Biotech Ab Polymer valves
US6602702B1 (en) 1999-07-16 2003-08-05 The University Of Texas System Detection system based on an analyte reactive particle
US6334859B1 (en) * 1999-07-26 2002-01-01 Zuli Holdings Ltd. Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments
US6969382B2 (en) 1999-07-26 2005-11-29 Zuli Holdings, Ltd. Method and apparatus for treating bodily tissues with medicinal substance
JP4397558B2 (en) * 1999-08-18 2010-01-13 マイクロチップス・インコーポレーテッド Thermally driven microchip chemical delivery device
DE19940241A1 (en) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Method for applying at least one active substance to a thin substrate forming a carrier layer involves use of liquid active substances which are applicable by bubble jet printing techniques
DE19940242A1 (en) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Applying a preparation in liquid phase containing active substances to a substrate constituting an adhesive therapeutic system involves use of a free jet similarly to bubble jet printing
KR100353877B1 (en) * 1999-08-30 2002-09-26 한국전자통신연구원 Method of manufacturing a drug delivery system formed microelectromechanical device
US6802811B1 (en) 1999-09-17 2004-10-12 Endoluminal Therapeutics, Inc. Sensing, interrogating, storing, telemetering and responding medical implants
GB9924334D0 (en) * 1999-10-15 1999-12-15 Secr Defence Pharmaceutical products and methods of fabrication therefor
US6413245B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
DE60016271T2 (en) * 1999-10-21 2005-12-01 Alcon Inc. drug delivery
JP2003513755A (en) * 1999-11-17 2003-04-15 マイクロチップス・インコーポレーテッド Microfabricated device for delivery of molecules into a carrier fluid
GB9928511D0 (en) * 1999-12-03 2000-02-02 Secr Defence Brit Orally administrable pharmaceutical product and method of fabrication therefor
EP1688132A3 (en) * 1999-12-10 2009-10-07 Massachussetts Institute of Technology Microchip devices for delivery of molecules and methods of fabrication thereof
DE60027458T2 (en) * 1999-12-10 2007-07-05 Massachusetts Institute Of Technology, Cambridge MICROCHIP DRUG DISABLING SYSTEMS AND MANUFACTURING METHOD
US6271038B1 (en) 1999-12-15 2001-08-07 Glaxo Wellcome Inc. Methods for high throughout determination and ranking of formulations and solubility
ATE403145T1 (en) 2000-01-31 2008-08-15 Univ Texas PORTABLE DEVICE HAVING A SENSOR ARRAY ARRANGEMENT
ATE499988T1 (en) * 2000-03-02 2011-03-15 Microchips Inc MICROMECHANICAL DEVICES AND METHODS FOR STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS
EP1132058A1 (en) * 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Intravascular prothesis
WO2001078626A1 (en) * 2000-04-13 2001-10-25 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6592519B1 (en) 2000-04-28 2003-07-15 Medtronic, Inc. Smart microfluidic device with universal coating
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2001091902A2 (en) * 2000-05-30 2001-12-06 Massachusetts Institute Of Technology Methods and devices for sealing microchip reservoir devices
US6540675B2 (en) * 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US6494882B1 (en) 2000-07-25 2002-12-17 Verimetra, Inc. Cutting instrument having integrated sensors
US20040092860A1 (en) * 2000-07-26 2004-05-13 Dev Nagendu B. Skin and muscle-targeted gene therapy by pulsed electrical field
US20020035346A1 (en) * 2000-08-14 2002-03-21 Reynolds John R. Drug release (delivery system)
AU2002211629A1 (en) * 2000-10-10 2002-04-22 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
US6773429B2 (en) 2000-10-11 2004-08-10 Microchips, Inc. Microchip reservoir devices and facilitated corrosion of electrodes
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
ATE300255T1 (en) * 2000-10-16 2005-08-15 Conor Medsystems Inc EXPANDABLE MEDICAL DEVICE FOR DELIVERING A MEDICINE
US6632175B1 (en) * 2000-11-08 2003-10-14 Hewlett-Packard Development Company, L.P. Swallowable data recorder capsule medical device
US6929636B1 (en) * 2000-11-08 2005-08-16 Hewlett-Packard Development Company, L.P. Internal drug dispenser capsule medical device
US8372139B2 (en) 2001-02-14 2013-02-12 Advanced Bio Prosthetic Surfaces, Ltd. In vivo sensor and method of making same
CA2436814A1 (en) * 2000-12-01 2002-07-18 Nephros Therapeutics, Inc. Intravascular drug delivery device and use therefor
WO2002044728A2 (en) * 2000-12-01 2002-06-06 Clemson University Chemical compositions comprising crystalline colloidal arrays
DE10061057A1 (en) * 2000-12-08 2002-06-13 Pharmed Holding Gmbh Chip systems for the controlled emission of chemically sensitive substances
DE10063612C2 (en) * 2000-12-20 2002-11-07 Fraunhofer Ges Forschung Microsystem for controlling the delivery of active ingredients from an active ingredient reservoir as well as implant with microsystem
US6666821B2 (en) 2001-01-08 2003-12-23 Medtronic, Inc. Sensor system
AU2002241834B2 (en) * 2001-01-09 2006-11-09 Microchips, Inc. Flexible microchip devices for opthalmic and other applications
US6650000B2 (en) * 2001-01-16 2003-11-18 International Business Machines Corporation Apparatus and method for forming a battery in an integrated circuit
GB0102171D0 (en) * 2001-01-27 2001-03-14 Krumme John A drug delivery service
US6562000B2 (en) 2001-02-02 2003-05-13 Medtronic, Inc. Single-use therapeutic substance delivery device with infusion rate control
US6749581B2 (en) 2001-02-02 2004-06-15 Medtronic, Inc. Variable infusion rate catheter
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
US6571125B2 (en) 2001-02-12 2003-05-27 Medtronic, Inc. Drug delivery device
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6964804B2 (en) * 2001-02-14 2005-11-15 Shipley Company, L.L.C. Micromachined structures made by combined wet and dry etching
US6858220B2 (en) 2001-02-28 2005-02-22 Second Sight Medical Products, Inc. Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating
US20030060695A1 (en) * 2001-03-07 2003-03-27 Connelly Patrick R. Implantable artificial organ devices
US7771468B2 (en) * 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
EP1387671A1 (en) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
DE10122839B4 (en) * 2001-05-11 2007-11-29 Qimonda Ag Process for separating semiconductor structures and semiconductor substrate prepared for singulation
US6973718B2 (en) * 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
WO2002099457A1 (en) * 2001-05-31 2002-12-12 Massachusetts Inst Technology Microchip devices with improved reservoir opening
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
DE60239868D1 (en) 2001-06-12 2011-06-09 Univ Johns Hopkins Med RESERVOIR DEVICE FOR INTRAOCULAR DRUG DELIVERY
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
WO2003002243A2 (en) * 2001-06-27 2003-01-09 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
WO2003032957A2 (en) * 2001-06-28 2003-04-24 Microchips, Inc. Methods for hermetically sealing microchip reservoir devices
DE10133870A1 (en) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmic agent, use of EGF for the treatment of dry eye syndrome and insert for the administration of EGF to the eye
ES2271301T3 (en) * 2001-07-23 2007-04-16 Alcon, Inc. FARMACO OFTALMICO SUPPLY DEVICE.
MXPA03011609A (en) 2001-07-23 2004-07-01 Alcon Inc Ophthalmic drug delivery device.
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US6663615B1 (en) * 2001-09-04 2003-12-16 The Ohio State University Dual stage microvalve and method of use
US20030055360A1 (en) * 2001-09-05 2003-03-20 Zeleznik Matthew A. Minimally invasive sensing system for measuring rigidity of anatomical matter
US7776379B2 (en) * 2001-09-19 2010-08-17 Medlogics Device Corporation Metallic structures incorporating bioactive materials and methods for creating the same
US20030060873A1 (en) * 2001-09-19 2003-03-27 Nanomedical Technologies, Inc. Metallic structures incorporating bioactive materials and methods for creating the same
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
EP1429737A1 (en) 2001-09-28 2004-06-23 McNEIL-PPC, INC. Modified release dosage forms
US7097775B2 (en) 2001-10-26 2006-08-29 Second Sight Medical Products, Inc. Coated microfluidic delivery system
US7020355B2 (en) * 2001-11-02 2006-03-28 Massachusetts Institute Of Technology Switchable surfaces
US20030105409A1 (en) 2001-11-14 2003-06-05 Donoghue John Philip Neurological signal decoding
AU2002353013A1 (en) 2001-12-03 2003-06-17 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
TW591267B (en) * 2002-01-11 2004-06-11 Chi Mei Optoelectronics Corp A liquid crystal display device
US7004928B2 (en) * 2002-02-08 2006-02-28 Rosedale Medical, Inc. Autonomous, ambulatory analyte monitor or drug delivery device
GB0204381D0 (en) * 2002-02-26 2002-04-10 Mcminn Derek J W Knee prosthesis
US20030171738A1 (en) * 2002-03-06 2003-09-11 Konieczynski David D. Convection-enhanced drug delivery device and method of use
US7108680B2 (en) * 2002-03-06 2006-09-19 Codman & Shurtleff, Inc. Closed-loop drug delivery system
JP2005522241A (en) * 2002-03-11 2005-07-28 アルコン,インコーポレイテッド Implantable drug delivery system
CA2523626A1 (en) 2002-04-26 2003-11-06 Board Of Regents, The University Of Texas System Method and system for the detection of cardiac risk factors
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2003105668A2 (en) * 2002-06-01 2003-12-24 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Injection devices and methods for testing implants and for unimpeded target location testing
US7280870B2 (en) * 2002-06-04 2007-10-09 Brown University Research Foundation Optically-connected implants and related systems and methods of use
US20070265582A1 (en) * 2002-06-12 2007-11-15 University Of Southern California Injection Devices for Unimpeded Target Location Testing
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
ES2295647T3 (en) * 2002-07-15 2008-04-16 Alcon, Inc. LIPOFIL PHARMACEUTICAL IMPLANT COMPOSITIONS, NOT POLYMER, FOR INTRAOCULAR USE
US6953455B2 (en) * 2002-07-30 2005-10-11 Hospira, Inc. Medicine delivery system
JP4436258B2 (en) * 2002-08-16 2010-03-24 マイクロチップス・インコーポレーテッド Controlled release device and method
AU2007200736B2 (en) * 2002-08-16 2008-09-18 Microchips, Inc. Controlled release device and method
JP3887588B2 (en) * 2002-08-30 2007-02-28 株式会社リガク Stress measurement method by X-ray diffraction
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
WO2004026174A2 (en) * 2002-09-20 2004-04-01 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
US20060100695A1 (en) * 2002-09-27 2006-05-11 Peacock James C Iii Implantable stent with modified ends
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
WO2004033034A1 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
ATE458534T1 (en) * 2002-10-04 2010-03-15 Microchips Inc MEDICAL DEVICE FOR CONTROLLED DRUG ADMINISTRATION AND CARDIAC MONITORING AND/OR HEART STIMULATION
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US7212851B2 (en) * 2002-10-24 2007-05-01 Brown University Research Foundation Microstructured arrays for cortex interaction and related methods of manufacture and use
US7087017B2 (en) * 2002-10-31 2006-08-08 Medtronic, Inc. Atraumatic sensor lead assemblies
IL152629A (en) * 2002-11-04 2010-12-30 Innoventions Ltd Implantable medical device for controlled release of a substance
US8221495B2 (en) 2002-11-07 2012-07-17 Abbott Laboratories Integration of therapeutic agent into a bioerodible medical device
US8524148B2 (en) 2002-11-07 2013-09-03 Abbott Laboratories Method of integrating therapeutic agent into a bioerodible medical device
PL376752A1 (en) 2002-11-07 2006-01-09 Abbott Laboratories Prosthesis having varied concentration of beneficial agent
US6902544B2 (en) * 2003-01-22 2005-06-07 Codman & Shurtleff, Inc. Troubleshooting accelerator system for implantable drug delivery pumps
US7483750B2 (en) * 2003-03-21 2009-01-27 Second Sight Medical Products, Inc. Transretinal implant and method of implantation
US7052652B2 (en) 2003-03-24 2006-05-30 Rosedale Medical, Inc. Analyte concentration detection devices and methods
CA2519711C (en) 2003-03-28 2012-01-17 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
DE10315538A1 (en) * 2003-04-04 2004-10-21 Siemens Ag Particles with a membrane
EP1638522B1 (en) * 2003-04-25 2011-01-12 Boston Scientific Scimed, Inc. Solid drug formulation and device for storage and controlled delivery thereof
US20040220531A1 (en) * 2003-05-01 2004-11-04 Bui Tuan S. System and method operating microreservoirs delivering medication in coordination with a pump delivering diluent
US7051654B2 (en) * 2003-05-30 2006-05-30 Clemson University Ink-jet printing of viable cells
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7442180B2 (en) * 2003-06-10 2008-10-28 Hewlett-Packard Development Company, L.P. Apparatus and methods for administering bioactive compositions
US7819847B2 (en) * 2003-06-10 2010-10-26 Hewlett-Packard Development Company, L.P. System and methods for administering bioactive compositions
US7226441B2 (en) * 2003-06-23 2007-06-05 Codman & Shurtleff, Inc. Catheter with block-overriding system
JP2007526019A (en) * 2003-07-10 2007-09-13 アルコン,インコーポレイティド Ophthalmic drug delivery device
US7114312B2 (en) * 2003-07-17 2006-10-03 Microchips, Inc. Low temperature methods for hermetically sealing reservoir devices
WO2005016558A2 (en) 2003-08-04 2005-02-24 Microchips, Inc. Methods for accelerated release of material from a reservoir device
ATE532454T1 (en) * 2003-09-11 2011-11-15 Theranos Inc MEDICAL DEVICE FOR ANALYTE MONITORING AND DRUG DELIVERY
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8095197B2 (en) * 2003-11-03 2012-01-10 Microchips, Inc. Medical device for sensing glucose
US7208172B2 (en) * 2003-11-03 2007-04-24 Medlogics Device Corporation Metallic composite coating for delivery of therapeutic agents from the surface of implantable devices
US20050143589A1 (en) * 2003-11-09 2005-06-30 Donoghue John P. Calibration systems and methods for neural interface devices
US20050113744A1 (en) * 2003-11-21 2005-05-26 Cyberkinetics, Inc. Agent delivery systems and related methods under control of biological electrical signals
US7751877B2 (en) * 2003-11-25 2010-07-06 Braingate Co., Llc Neural interface system with embedded id
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
US20050119723A1 (en) * 2003-11-28 2005-06-02 Medlogics Device Corporation Medical device with porous surface containing bioerodable bioactive composites and related methods
WO2005059551A2 (en) * 2003-12-11 2005-06-30 Board Of Regents, The University Of Texas System Method and system for the analysis of saliva using a sensor array
US7647097B2 (en) * 2003-12-29 2010-01-12 Braingate Co., Llc Transcutaneous implant
EP1713453B1 (en) * 2004-02-13 2008-11-19 Conor Medsystems, Inc. Implantable drug delivery device including wire filaments
US7364564B2 (en) * 2004-03-02 2008-04-29 Becton, Dickinson And Company Implant having MEMS flow module with movable, flow-controlling baffle
US7548092B2 (en) 2004-02-25 2009-06-16 Ternarylogic Llc Implementing logic functions with non-magnitude based physical phenomena
US7696785B2 (en) * 2004-02-25 2010-04-13 Ternarylogic Llc Implementing logic functions with non-magnitude based physical phenomena
US7563460B2 (en) * 2004-02-26 2009-07-21 Med Five, Inc. Enteric coated oral pharmaceutical to erode kidney stones
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
US8105849B2 (en) 2004-02-27 2012-01-31 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements
US20050203366A1 (en) * 2004-03-12 2005-09-15 Donoghue John P. Neurological event monitoring and therapy systems and related methods
WO2008035343A2 (en) * 2006-09-21 2008-03-27 Technion Research & Development Foundation Ltd. Artificial receptors
US8354066B2 (en) 2004-03-24 2013-01-15 Technion Research & Development Foundation Ltd. Artificial receptors
US20070036835A1 (en) * 2004-07-19 2007-02-15 Microchips, Inc. Hermetically Sealed Devices for Controlled Release or Exposure of Reservoir Contents
US7537590B2 (en) * 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20060049957A1 (en) * 2004-08-13 2006-03-09 Surgenor Timothy R Biological interface systems with controlled device selector and related methods
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
EP1791643B1 (en) * 2004-09-01 2009-03-11 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
US20100164548A1 (en) * 2004-09-08 2010-07-01 Ternarylogic Llc Implementing Logic Functions With Non-Magnitude Based Physical Phenomena
GB2418144A (en) * 2004-09-17 2006-03-22 Psimedica Ltd Medical device for delivery of beneficial substance
US8271093B2 (en) 2004-09-17 2012-09-18 Cardiac Pacemakers, Inc. Systems and methods for deriving relative physiologic measurements using a backend computing system
EP1827207A2 (en) 2004-10-04 2007-09-05 Cyberkinetics Neurotechnology Systems, Inc. Biological interface system
DE102004050457A1 (en) * 2004-10-12 2006-04-13 Capsulution Nanoscience Ag Segmented device for the sustained release of molecules in the tangential direction through thin films and applications thereof
CN101437856A (en) * 2004-10-14 2009-05-20 塔夫茨大学信托人 Electrochemically degradable polymers
WO2006050106A1 (en) * 2004-10-28 2006-05-11 Microchips, Inc. Orthopedic and dental implant devices providing controlled drug delivery
KR101211576B1 (en) 2004-11-04 2012-12-12 마이크로칩스 인코포레이티드 Compression and cold weld sealing methods and devices
EP1819278A4 (en) 2004-11-15 2009-04-08 Izex Technologies Inc Instrumented orthopedic and other medical implants
US8308794B2 (en) 2004-11-15 2012-11-13 IZEK Technologies, Inc. Instrumented implantable stents, vascular grafts and other medical devices
US7413846B2 (en) * 2004-11-15 2008-08-19 Microchips, Inc. Fabrication methods and structures for micro-reservoir devices
US7813808B1 (en) 2004-11-24 2010-10-12 Remon Medical Technologies Ltd Implanted sensor system with optimized operational and sensing parameters
US7991461B2 (en) * 2005-01-06 2011-08-02 Braingate Co., Llc Patient training routine for biological interface system
US7901368B2 (en) 2005-01-06 2011-03-08 Braingate Co., Llc Neurally controlled patient ambulation system
US8095209B2 (en) * 2005-01-06 2012-01-10 Braingate Co., Llc Biological interface system with gated control signal
US20060189901A1 (en) * 2005-01-10 2006-08-24 Flaherty J C Biological interface system with surrogate controlled device
US20060167564A1 (en) * 2005-01-10 2006-07-27 Flaherty J C Limb and digit movement system
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
US7881780B2 (en) * 2005-01-18 2011-02-01 Braingate Co., Llc Biological interface system with thresholded configuration
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US20090088679A1 (en) * 2005-02-07 2009-04-02 Massachusetts Institute Of Technology Electronically-Degradable Layer-by-Layer Thin Films
US20100001104A1 (en) * 2005-03-29 2010-01-07 Waterbury Companies, Inc. Precision release vaporization device
US20100204551A1 (en) * 2008-10-22 2010-08-12 Martin William Roche Detection, Prevention and Treatment of Infections in Implantable Devices
US7584907B2 (en) 2005-03-29 2009-09-08 Contadini Carl D Precision release aerosol device
EP1875560A4 (en) * 2005-04-05 2011-02-09 Univ Ohio State Diffusion delivery systems and methods of fabrication
US20060226575A1 (en) * 2005-04-07 2006-10-12 Mariam Maghribi Micro-fabrication of bio-degradable polymeric implants
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US8841076B2 (en) 2005-05-09 2014-09-23 Theranos, Inc. Systems and methods for conducting animal studies
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US20060281187A1 (en) 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
WO2007001624A2 (en) * 2005-06-28 2007-01-04 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
JP2009500098A (en) * 2005-07-05 2009-01-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Device for controlled release of a certain amount of substance
JP5265359B2 (en) * 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー Intravesical drug delivery device and method
US20070055352A1 (en) * 2005-09-07 2007-03-08 Wendy Naimark Stent with pockets for containing a therapeutic agent
US7742815B2 (en) 2005-09-09 2010-06-22 Cardiac Pacemakers, Inc. Using implanted sensors for feedback control of implanted medical devices
US8801631B2 (en) 2005-09-30 2014-08-12 Intuity Medical, Inc. Devices and methods for facilitating fluid transport
CA2623589C (en) 2005-09-30 2014-07-22 Intuity Medical, Inc. Catalysts for body fluid sample extraction
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007042982A2 (en) * 2005-10-11 2007-04-19 Koninklijke Philips Electronics N.V. Individually activated sensors for implantable devices
WO2007047556A2 (en) * 2005-10-14 2007-04-26 Microchips, Inc. Passive wear-indicating sensor for implantable prosthetic device
US20070106143A1 (en) * 2005-11-08 2007-05-10 Flaherty J C Electrode arrays and related methods
US8992511B2 (en) * 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US7699834B2 (en) 2005-11-09 2010-04-20 Searete Llc Method and system for control of osmotic pump device
US20070106275A1 (en) 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Reaction device controlled by RF control signal
US8083710B2 (en) * 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8936590B2 (en) 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US9067047B2 (en) 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US20070112421A1 (en) * 2005-11-14 2007-05-17 O'brien Barry Medical device with a grooved surface
US20070156126A1 (en) * 2005-12-29 2007-07-05 Flaherty J C Medical device insertion system and related methods
US20100023021A1 (en) * 2005-12-27 2010-01-28 Flaherty J Christopher Biological Interface and Insertion
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048419B2 (en) 2006-02-02 2011-11-01 Innovative Biotherapies, Inc. Extracorporeal cell-based therapeutic device and delivery system
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20070191816A1 (en) * 2006-02-13 2007-08-16 Boston Scientific Scimed, Inc. Radio frequency induced drug elution
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
AU2007238608A1 (en) 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
JP2009536064A (en) * 2006-05-05 2009-10-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Apparatus and method for controlled release of a quantity of a substance
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20070275035A1 (en) * 2006-05-24 2007-11-29 Microchips, Inc. Minimally Invasive Medical Implant Devices for Controlled Drug Delivery
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
EP1867990A1 (en) * 2006-06-14 2007-12-19 Koninklijke Philips Electronics N.V. Sensitive assay through amplification of a label signal
RU2009101475A (en) * 2006-06-20 2010-07-27 Конинклейке Филипс Электроникс, Н.В. (Nl) ELECTRONIC CAPSULE AND METHOD FOR TREATING A GASTROINTESTINAL DISEASE
WO2008008845A2 (en) * 2006-07-11 2008-01-17 Microchips, Inc. Multi-reservoir pump device for dialysis, biosensing, or delivery of substances
US20150005720A1 (en) * 2006-07-18 2015-01-01 E Ink California, Llc Electrophoretic display
US7955268B2 (en) 2006-07-21 2011-06-07 Cardiac Pacemakers, Inc. Multiple sensor deployment
WO2008017028A2 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
WO2008017042A1 (en) * 2006-08-03 2008-02-07 Microchips, Inc. Cardiac biosensor devices and methods
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
ATE517590T1 (en) 2006-09-15 2011-08-15 Boston Scient Ltd BIOLOGICALLY ERODABLE ENDOPROTHESES
WO2008034048A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprosthesis with biostable inorganic layers
JP2010503482A (en) 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
US8012744B2 (en) 2006-10-13 2011-09-06 Theranos, Inc. Reducing optical interference in a fluidic device
US20080113391A1 (en) * 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
JP2010509988A (en) * 2006-11-16 2010-04-02 ボストン サイエンティフィック リミテッド Stents that release therapeutic agents to the outer and luminal sides at different times
CA2674195A1 (en) 2006-12-28 2008-07-10 Boston Scientific Limited Bioerodible endoprostheses and methods of making same
DK2148691T3 (en) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
DK2191001T3 (en) 2007-04-09 2016-09-19 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US8649840B2 (en) 2007-06-07 2014-02-11 Microchips, Inc. Electrochemical biosensors and arrays
WO2008157372A2 (en) 2007-06-14 2008-12-24 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
DE102007031549B4 (en) * 2007-07-06 2021-07-08 Robert Bosch Gmbh Single crystal silicon device and method of making a single crystal silicon device
DE102007032688A1 (en) * 2007-07-13 2009-01-22 Biotronik Vi Patent Ag Implant and system of an implant and an excitation device
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
JP5588344B2 (en) 2007-08-14 2014-09-10 フレッド ハッチンソン キャンサー リサーチ センター Needle array assembly and method for delivering therapeutic agents
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8753304B2 (en) 2007-08-17 2014-06-17 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8706211B2 (en) * 2007-08-17 2014-04-22 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having self-cleaning surfaces
US8702640B2 (en) 2007-08-17 2014-04-22 The Invention Science Fund I, Llc System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
EP2052700A1 (en) * 2007-09-26 2009-04-29 Microchips, Inc. Drug delivery device and method for use with prosthetic device implantation
EP2195466B1 (en) 2007-10-01 2012-10-10 Longhorn Vaccines & Diagnostics, LLC Method of storing biological specimens
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2009046227A1 (en) 2007-10-02 2009-04-09 Theranos, Inc. Modular point-of-care devices and uses thereof
US8303573B2 (en) * 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) * 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
AU2008318833B2 (en) * 2007-10-29 2014-02-13 Zimmer, Inc. Medical implants and methods for delivering biologically active agents
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8989858B2 (en) 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8233976B2 (en) 2007-12-05 2012-07-31 The Invention Science Fund I, Llc System for transdermal chemical modulation of neural activity
US8170659B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc Method for thermal modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8180446B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
MX348005B (en) 2007-12-11 2017-05-23 Massachusetts Inst Technology Implantable drug delivery device ant) methods for treatment of the bladder and other body vestcles or lumens.
US7722661B2 (en) * 2007-12-19 2010-05-25 Boston Scientific Scimed, Inc. Stent
ES2371380T3 (en) * 2008-01-24 2011-12-30 Boston Scientific Scimed, Inc. STENT TO SUPPLY A THERAPEUTIC AGENT FROM A SIDE SURFACE OF A STENT STEM.
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
WO2009099935A2 (en) * 2008-02-01 2009-08-13 Boston Scientific Scimed, Inc. Drug-coated medical devices for differential drug release
EP2242538B1 (en) 2008-02-11 2016-04-06 Cardiac Pacemakers, Inc. Methods of monitoring hemodynamic status for ryhthm discrimination within the heart
WO2009102640A1 (en) 2008-02-12 2009-08-20 Cardiac Pacemakers, Inc. Systems and methods for controlling wireless signal transfers between ultrasound-enabled medical devices
US7981106B2 (en) * 2008-02-26 2011-07-19 Pinchas Gilad Electronically-controlled device for release of drugs, proteins, and other organic or inorganic chemicals
US20090270795A1 (en) * 2008-04-23 2009-10-29 Medtronic, Inc. Method for welding a barrier in an implantable drug delivery device
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
EP2293719B1 (en) 2008-05-30 2015-09-09 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
DK3639744T3 (en) 2008-06-06 2022-02-21 Intuity Medical Inc BLOOD GLUCOSE METER AND METHOD OF USE
US9636051B2 (en) 2008-06-06 2017-05-02 Intuity Medical, Inc. Detection meter and mode of operation
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
CA2728215A1 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US20100022487A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
EP2320962A2 (en) * 2008-07-31 2011-05-18 Boston Scientific Scimed, Inc. Medical devices for therapeutic agent delivery
KR101689786B1 (en) 2008-08-09 2016-12-26 메사츄세츠 인스티튜트 어브 테크놀로지 Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
US9198875B2 (en) * 2008-08-17 2015-12-01 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
JP5465252B2 (en) 2008-10-10 2014-04-09 カーディアック ペースメイカーズ, インコーポレイテッド System and method for determining cardiac output using pulmonary artery pressure measurements
US20100118316A1 (en) * 2008-11-13 2010-05-13 Tokyo Electron Limited Auto focus array detector optimized for operating objectives
US8632470B2 (en) 2008-11-19 2014-01-21 Cardiac Pacemakers, Inc. Assessment of pulmonary vascular resistance via pulmonary artery pressure
US20110295090A1 (en) 2008-12-04 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US20110208021A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
WO2010065135A1 (en) 2008-12-04 2010-06-10 Searete, Llc System, devices, and methods including actively-controllable sterilizing excitation delivery implants
US20110208023A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US20110208026A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8317737B2 (en) * 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8167871B2 (en) * 2009-02-25 2012-05-01 The Invention Science Fund I, Llc Device for actively removing a target cell from blood or lymph of a vertebrate subject
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
WO2010110916A2 (en) * 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
WO2010110919A1 (en) 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Monitoring of implants and other devices
FR2945097B1 (en) * 2009-04-30 2011-06-03 Commissariat Energie Atomique MICROFLUIDIC VALVE FOR SINGLE USE.
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
TW201043224A (en) * 2009-06-06 2010-12-16 Univ Nat Taiwan Drug delivery chip and fabricating method thereof
AU2010265863C1 (en) 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP2496936B1 (en) 2009-10-16 2018-02-21 Microchips Biotech, Inc. Multi-channel potentiostat for biosensor arrays and method of operation
CA3081708C (en) * 2009-10-19 2023-10-03 Theranos Ip Company, Llc Integrated health data capture and analysis system
EP3106871B1 (en) 2009-11-30 2021-10-27 Intuity Medical, Inc. A method of verifying the accuracy of the operation of an analyte monitoring device
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8673018B2 (en) * 2010-02-05 2014-03-18 AMx Tek LLC Methods of using water-soluble inorganic compounds for implants
US8911426B2 (en) 2010-02-08 2014-12-16 On Demand Therapeutics, Inc. Low-permeability, laser-activated drug delivery device
US8828246B2 (en) * 2010-02-18 2014-09-09 Anpac Bio-Medical Science Co., Ltd. Method of fabricating micro-devices
WO2011119573A1 (en) 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
ES2634551T3 (en) * 2010-04-03 2017-09-28 Praful Doshi Methods for coating a contact lens
US20110251568A1 (en) * 2010-04-08 2011-10-13 Beeley Nathan R F Punctal plugs for controlled release of therapeutic agents
CN102918152B (en) 2010-04-23 2016-04-13 佛罗里达大学研究基金公司 Be used for the treatment of Lay Bai Shi congenital amaurosis-1(LCA1) RAAV-guanylate enzyme composition and method
EP3444346B1 (en) 2010-04-23 2022-07-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders
CA3049237A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CH703278B1 (en) 2010-06-15 2016-11-15 Csem Centre Suisse D'electronique Et De Microtechnique Sa - Rech Et Développement Device and platform for multiplex analysis.
US10330667B2 (en) 2010-06-25 2019-06-25 Intuity Medical, Inc. Analyte monitoring methods and systems
PT2600930T (en) 2010-08-05 2021-03-22 Forsight Vision4 Inc Injector apparatus and method for drug delivery
HUE057267T2 (en) 2010-08-05 2022-05-28 Forsight Vision4 Inc Apparatus to treat an eye
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012019083A2 (en) 2010-08-06 2012-02-09 Microchips, Inc. Biosensor membrane composition, biosensor, and methods for making same
EP2616166A1 (en) * 2010-09-13 2013-07-24 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Antimicrobial membrane containing silver nanoparticles
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
CN103282020B (en) 2010-11-01 2016-10-26 普西维达公司 Can the silicon-based devices of bioerosion for deliver therapeutic agent
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US8679093B2 (en) 2010-11-23 2014-03-25 Microchips, Inc. Multi-dose drug delivery device and method
RU2620032C2 (en) 2011-01-10 2017-05-22 Аллерган, Инк. Lidocain reception diagram for application in long-term treatment of pain in bladder and irritation during urination
RU2620922C2 (en) 2011-01-21 2017-05-30 Теранос, Инк. Systems and methods for optimization of sample use
JP6043730B2 (en) 2011-02-04 2016-12-14 タリス バイオメディカル エルエルシー Implantable device for controlled release of low solubility drugs
EP2699266B1 (en) 2011-04-21 2019-06-12 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2012145624A2 (en) 2011-04-21 2012-10-26 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
PL2736357T3 (en) 2011-07-26 2019-02-28 The Curators Of The University Of Missouri Engineered comestible meat
CA3154143A1 (en) 2011-08-03 2013-02-07 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc Small molecule delivery with implantable therapeutic device
US10427153B2 (en) 2011-08-25 2019-10-01 Microchips Biotech, Inc. Systems and methods for sealing a plurality of reservoirs of a microchip element with a sealing grid
SG11201400907PA (en) 2011-08-25 2014-07-30 Microchips Inc Space-efficient containment devices and method of making same
US20140221963A1 (en) * 2011-08-25 2014-08-07 Edy E. Soffer Use of eating detection to control the release of biologically active agents
HUE054578T2 (en) 2011-09-16 2021-09-28 Forsight Vision4 Inc Fluid exchange apparatus
CN104023760A (en) 2011-10-28 2014-09-03 普莱萨格生命科学公司 Methods for drug delivery
US8414654B1 (en) * 2011-11-23 2013-04-09 Amendia, Inc. Bone implants and method of manufacture
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
US20130184593A1 (en) * 2011-12-30 2013-07-18 Kibur Medical, Inc. Implantable Devices And Methods For The Evaluation of Active Agents
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc Composite antigenic sequences and vaccines
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9314571B1 (en) 2012-02-10 2016-04-19 Mphase Technologies, Inc. Drug delivery system
EP2841056A4 (en) 2012-04-23 2015-09-16 Massachusetts Inst Technology Stable layer-by-layer coated particles
US9101707B2 (en) 2012-04-27 2015-08-11 Gregory Zeltser Implantable bioartificial perfusion system
CA2875146C (en) * 2012-05-30 2022-03-22 The Regents Of The University Of California Bioactive agent delivery devices and methods of making and using the same
US9144488B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with analyte sensors responsive to external power source
US8808373B2 (en) 2012-06-13 2014-08-19 Elwha Llc Breast implant with regionalized analyte sensors responsive to external power source
US8795359B2 (en) 2012-06-13 2014-08-05 Elwha Llc Breast implant with regionalized analyte sensors and internal power source
US8790400B2 (en) 2012-06-13 2014-07-29 Elwha Llc Breast implant with covering and analyte sensors responsive to external power source
US9144489B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with covering, analyte sensors and internal power source
US9211185B2 (en) 2012-06-13 2015-12-15 Elwha Llc Breast implant with analyte sensors and internal power source
US9136160B2 (en) * 2012-06-29 2015-09-15 Institute of Microelectronics, Chinese Academy of Sciences Solid hole array and method for forming the same
US9457128B2 (en) 2012-09-07 2016-10-04 President And Fellows Of Harvard College Scaffolds comprising nanoelectronic components for cells, tissues, and other applications
US9786850B2 (en) * 2012-09-07 2017-10-10 President And Fellows Of Harvard College Methods and systems for scaffolds comprising nanoelectronic components
CN110882376B (en) 2012-11-15 2023-10-20 阿佩利斯制药公司 Cell-reactive, long-acting or targeted compstatin analogs and related compositions and methods
SG11201504886SA (en) 2012-12-21 2015-07-30 Microchips Biotech Inc Implantable medical device for minimally-invasive insertion
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
MX2015010152A (en) 2013-02-06 2015-12-16 California Inst Of Techn Miniaturized implantable electrochemical sensor devices.
FR3002694A1 (en) 2013-02-25 2014-08-29 Commissariat Energie Atomique ENERGY STORAGE AND TRANSPORT SYSTEM, IN PARTICULAR FOR AN IMPLANTABLE DEVICE, AND METHOD FOR MANUFACTURING SAME
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
SG11201506675PA (en) 2013-02-28 2015-09-29 Microchips Biotech Inc Implantable medical device for minimally-invasive insertion
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc Bioerodible silicon-based compositions for delivery of therapeutic agents
US10315019B2 (en) 2013-03-15 2019-06-11 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
EP2978393B1 (en) 2013-03-28 2023-12-27 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
WO2014165822A1 (en) 2013-04-04 2014-10-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, systems, devices, and methods for endoluminal electropolymeric paving and sealing
AU2014250792B2 (en) 2013-04-12 2018-05-10 The Board Of Trustees Of The University Of Illinois Materials, electronic systems and modes for active and passive transience
US10009996B2 (en) 2013-05-22 2018-06-26 Transient Electronics, Inc. Controlled transformation of non-transient electronics
US10729386B2 (en) 2013-06-21 2020-08-04 Intuity Medical, Inc. Analyte monitoring system with audible feedback
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA3173027A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
WO2015038988A1 (en) 2013-09-13 2015-03-19 Modern Meadow, Inc. Edible and animal-product-free microcarriers for engineered meat
EP3102043A4 (en) 2014-02-05 2017-08-09 Modern Meadow, Inc. Dried food products formed from cultured muscle cells
JP6756700B2 (en) 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
KR101967133B1 (en) * 2014-04-22 2019-04-10 한국과학기술원 Method for manufacturing a flexible drug delivery device and the flexible drug delivery device manufactured by the same
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
KR102416726B1 (en) 2014-07-15 2022-07-05 포사이트 비젼4, 인크. Ocular implant delivery device and method
EP3169660A1 (en) 2014-07-16 2017-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016054557A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Novel high efficiency library-identified aav vectors
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
EP3217924A4 (en) 2014-11-10 2018-07-11 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
CN107249646B (en) 2014-12-16 2021-06-29 内布拉斯加大学董事会 Gene therapy for juvenile batten disease
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10368788B2 (en) * 2015-07-23 2019-08-06 California Institute Of Technology System and methods for wireless drug delivery on command
ES2842501T5 (en) 2015-09-21 2023-04-13 Modern Meadow Inc Fiber Reinforced Fabric Composite Materials
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
WO2017096304A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
BR112017016266A2 (en) 2016-02-15 2018-03-27 Modern Meadow, Inc. method for producing a biofabricated material.
AU2017228413A1 (en) 2016-03-03 2018-08-23 University Of Massachusetts Closed-ended linear duplex DNA for non-viral gene transfer
WO2017176886A1 (en) 2016-04-05 2017-10-12 Forsight Vision4, Inc. Implantable ocular drug delivery devices
FR3054137B1 (en) 2016-07-21 2021-08-27 Univ Angers LOCOREGIONAL INJECTION IMPLANTABLE MEDICAL DEVICE
US10406336B2 (en) * 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CA3037337A1 (en) 2016-09-19 2018-03-22 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
JP2019530463A (en) 2016-10-13 2019-10-24 ユニバーシティ オブ マサチューセッツ AAV capsid design
WO2018106632A1 (en) 2016-12-05 2018-06-14 Corsair Pharma, Inc. Dermal and transdermal administration of treprostinil and salts thereof
CN110446491A (en) 2017-03-24 2019-11-12 伊英克加利福尼亚有限责任公司 Adjust the micro unit delivery system comprising charged particle or magnetic particle that active material gives rate
TWI753284B (en) 2017-03-24 2022-01-21 美商伊英克加利福尼亞有限責任公司 Active molecule delivery system
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CN108968976B (en) 2017-05-31 2022-09-13 心脏起搏器股份公司 Implantable medical device with chemical sensor
US10737090B2 (en) 2017-07-11 2020-08-11 Medtronic, Inc. External defibrillation electrode conductive electrolyte dispersal pad
US10508755B2 (en) * 2017-07-21 2019-12-17 International Business Machines Corporation Fluid delivery device with hydrophobic surface
EP3658204A4 (en) * 2017-07-24 2021-06-23 California Institute of Technology Low power, chemically amplified, electrically removable barrier
CN109381195B (en) 2017-08-10 2023-01-10 心脏起搏器股份公司 Systems and methods including electrolyte sensor fusion
CN109419515B (en) 2017-08-23 2023-03-24 心脏起搏器股份公司 Implantable chemical sensor with staged activation
CA3071888A1 (en) * 2017-09-26 2019-04-04 Medtronic Minimed, Inc. Waferscale physiological characteristic sensor package with integrated wireless transmitter
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
AU2018253595A1 (en) 2017-11-13 2019-05-30 Modern Meadow, Inc. Biofabricated leather articles having zonal properties
TWI682787B (en) 2017-11-14 2020-01-21 美商伊英克加利福尼亞有限責任公司 Electrophoretic active delivery system including porous conductive electrode layer
KR20200093581A (en) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. Fluid exchange devices and methods of use for scalable port delivery systems
EP3713558A4 (en) 2017-11-22 2021-10-13 Panorama Research Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders
CN109864746B (en) 2017-12-01 2023-09-29 心脏起搏器股份公司 Multimode analyte sensor for medical devices
CN109864747B (en) 2017-12-05 2023-08-25 心脏起搏器股份公司 Multimode analyte sensor optoelectronic interface
WO2019183605A1 (en) 2018-03-23 2019-09-26 University Of Massachusetts Gene therapeutics for treating bone disorders
US11472848B2 (en) 2018-04-27 2022-10-18 University Of Massachusetts AAV capsids identified by in vivo library selection
WO2020112967A1 (en) 2018-11-29 2020-06-04 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
JP2022516945A (en) 2019-01-09 2022-03-03 トゥウェンティ トゥウェンティ セラピューティクス エルエルシー Eye-wearing device for therapeutic agent release
WO2020146358A1 (en) 2019-01-09 2020-07-16 Verily Life Sciences Llc Programmable therapeutic agent delivery from eye mounted device
CA3121853A1 (en) 2019-01-17 2020-07-23 Modern Meadow, Inc. Layered collagen materials and methods of making the same
US20220054655A1 (en) 2019-02-22 2022-02-24 University Of Massachusetts Oxr1 gene therapy
WO2021050970A1 (en) 2019-09-13 2021-03-18 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
JP2022553563A (en) * 2019-11-01 2022-12-23 ダーレ エムビー インコーポレイテッド Two-step microchip drug delivery device and method
KR20220074962A (en) 2019-11-27 2022-06-03 이 잉크 캘리포니아 엘엘씨 Benefit agent delivery system comprising microcells having an electro-erodible sealing layer
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP4126911A1 (en) 2020-03-31 2023-02-08 University of Massachusetts Aav capsids variants and uses thereof
TW202208418A (en) 2020-05-21 2022-03-01 美國德州系統大學評議委員會 T cell receptors with vgll1 specificity and uses thereof
CA3192052A1 (en) 2020-08-17 2022-02-24 Massachusetts Institute Of Technology Shank3 gene therapy approaches
BR102020019674A2 (en) * 2020-09-27 2022-04-12 Christiane Dias Maués Cylindrical tubular prosthetic device; and prosthetic device with non-polymeric biological matrix support for drug delivery, induced by microchip and nanosensors for remote operability and monitoring
WO2022093547A1 (en) 2020-10-29 2022-05-05 E Ink California, Llc Microcell systems for delivering hydrophilic active molecules
EP4236926A1 (en) 2020-10-29 2023-09-06 E Ink California, LLC Microcell systems for delivering benefit agents
CN116829168A (en) 2020-11-29 2023-09-29 海必恩制药公司 Use of cyclosporin analogs as antithrombotic agents
KR20230117177A (en) 2020-12-03 2023-08-07 유니버시티 오브 매사추세츠 Development of novel gene therapy for progressive ossifying fibrous dysplasia
AU2022272489A1 (en) 2021-05-10 2023-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions for treating neurological conditions
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692027A (en) * 1971-04-23 1972-09-19 Everett H Ellinwood Jr Implanted medication dispensing device and method
US4146029A (en) * 1974-04-23 1979-03-27 Ellinwood Jr Everett H Self-powered implanted programmable medication system and method
US4003379A (en) * 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
US4360019A (en) * 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4731051A (en) * 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
JPS57163309A (en) * 1981-04-01 1982-10-07 Olympus Optical Co Ltd Capsule apparatus for medical use
GB8422876D0 (en) * 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4585652A (en) * 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US4731049A (en) * 1987-01-30 1988-03-15 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US4994023A (en) * 1989-08-08 1991-02-19 Wellinghoff Stephen T Electrochemical drug release and article
US5041107A (en) * 1989-10-06 1991-08-20 Cardiac Pacemakers, Inc. Electrically controllable, non-occluding, body implantable drug delivery system
US5170801A (en) * 1990-10-02 1992-12-15 Glaxo Inc. Medical capsule device actuated by radio-frequency (rf) signal
US5196002A (en) * 1990-10-09 1993-03-23 University Of Utah Research Foundation Implantable drug delivery system with piston acutation
US5167625A (en) * 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
US5254081A (en) * 1991-02-01 1993-10-19 Empi, Inc. Multiple site drug iontophoresis electronic device and method
US5391164A (en) * 1991-05-03 1995-02-21 Giampapa; Vincent C. Subcutaneous implantable multiple-agent delivery system
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
WO1993003790A1 (en) * 1991-08-26 1993-03-04 Rutgers, The State University Of New Jersey Iontotherapeutic device and process
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5366454A (en) * 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5368704A (en) * 1993-08-06 1994-11-29 Teknekron Corporation Micro-electrochemical valves and method
US5900160A (en) * 1993-10-04 1999-05-04 President And Fellows Of Harvard College Methods of etching articles via microcontact printing
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5518680A (en) * 1993-10-18 1996-05-21 Massachusetts Institute Of Technology Tissue regeneration matrices by solid free form fabrication techniques
US5651900A (en) * 1994-03-07 1997-07-29 The Regents Of The University Of California Microfabricated particle filter
US5985328A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5660680A (en) * 1994-03-07 1997-08-26 The Regents Of The University Of California Method for fabrication of high vertical aspect ratio thin film structures
US5798042A (en) * 1994-03-07 1998-08-25 Regents Of The University Of California Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5893974A (en) * 1994-03-07 1999-04-13 Regents Of University Of California Microfabricated capsules for immunological isolation of cell transplants
US5992769A (en) * 1995-06-09 1999-11-30 The Regents Of The University Of Michigan Microchannel system for fluid delivery
SE9502258D0 (en) * 1995-06-21 1995-06-21 Pharmacia Biotech Ab Method for the manufacture of a membrane-containing microstructure
US5830659A (en) * 1996-09-13 1998-11-03 University Of Utah Research Foundation Active microtubule-based separations by kinesins
US5938923A (en) * 1997-04-15 1999-08-17 The Regents Of The University Of California Microfabricated filter and capsule using a substrate sandwich

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese

Also Published As

Publication number Publication date
US5797898A (en) 1998-08-25
WO1998000107A3 (en) 1998-06-11
DE69712063D1 (en) 2002-05-23
DK0914092T3 (en) 2002-08-12
ES2176768T3 (en) 2002-12-01
PT914092E (en) 2002-09-30
US6123861A (en) 2000-09-26
WO1998000107A2 (en) 1998-01-08
EP0914092A2 (en) 1999-05-12
ATE216219T1 (en) 2002-05-15
DE69712063T2 (en) 2002-10-24
CA2258898A1 (en) 1998-01-08
JP2006096760A (en) 2006-04-13
JP2000513725A (en) 2000-10-17
EP0914092B1 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
CA2258898C (en) Microchip drug delivery devices
WO1998000107A9 (en) Microchip drug delivery devices
US7892221B2 (en) Method of controlled drug delivery from implant device
US6669683B2 (en) Thermally-activated microchip chemical delivery devices
US6875208B2 (en) Microchip devices with improved reservoir opening
US7041130B2 (en) Stent for controlled release of drug
EP1235560B1 (en) Microchip devices for delivery of molecules and methods of fabrication thereof
US20210128463A1 (en) Two Stage Microchip Drug Delivery Device and Methods
Garg et al. Microchip: A ubiquitous technique for drug delivery
Vachhani et al. Microchip as a Controlled Drug Delivery Device

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170704